Tscan Therapeutics Stock Performance
| TCRX Stock | USD 2.40 0.06 2.44% |
The entity has a beta of 0.77, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tscan Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tscan Therapeutics is expected to be smaller as well. At this point, Tscan Therapeutics has a negative expected return of -1.1%. Please make sure to validate Tscan Therapeutics' coefficient of variation, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if Tscan Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Tscan Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (2.44) | Five Day Return (12.73) | Year To Date Return (22.33) | Ten Year Return (77.14) | All Time Return (77.14) |
1 | Disposition of 10000 shares by Lynx1 Capital Management Lp of Tscan Therapeutics at 2.5148 subject to Rule 16b-3 | 11/01/2024 |
2 | TScan Therapeutics Soars 7.6 percent Is Further Upside Left in the Stock | 11/07/2024 |
3 | Checkpoint Capital L.P. Acquires Shares of 825,341 TScan Therapeutics, Inc. | 12/02/2024 |
4 | TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years | 12/05/2024 |
5 | TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meet... | 12/09/2024 |
6 | Acquisition by Lynx1 Capital Management Lp of 31800 shares of Tscan Therapeutics at 3.0072 subject to Rule 16b-3 | 12/12/2024 |
7 | Acquisition by Lynx1 Capital Management Lp of 100000 shares of Tscan Therapeutics at 2.9014 subject to Rule 16b-3 | 12/13/2024 |
8 | Lynx1 Capital Management LP Increases Stake in TScan Therapeutics Inc - GuruFocus.com | 12/16/2024 |
9 | TScan Therapeutics Announces 30 Million Registered Direct Offering at a 37 percent Premium | 12/26/2024 |
10 | Heres Why TScan Therapeutics is Poised for a Turnaround After Losing -5.63 percent in 4 Weeks | 01/10/2025 |
11 | TScan Therapeutics, Inc.s recent 14 percent pullback adds to one-year year losses, institutional owners may take drastic measures | 01/17/2025 |
| Begin Period Cash Flow | 125.1 M |
Tscan |
Tscan Therapeutics Relative Risk vs. Return Landscape
If you would invest 527.00 in Tscan Therapeutics on October 21, 2024 and sell it today you would lose (287.00) from holding Tscan Therapeutics or give up 54.46% of portfolio value over 90 days. Tscan Therapeutics is currently does not generate positive expected returns and assumes 5.3722% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Tscan, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tscan Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tscan Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tscan Therapeutics, and traders can use it to determine the average amount a Tscan Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2056
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TCRX |
Estimated Market Risk
| 5.37 actual daily | 47 53% of assets are more volatile |
Expected Return
| -1.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Tscan Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tscan Therapeutics by adding Tscan Therapeutics to a well-diversified portfolio.
Tscan Therapeutics Fundamentals Growth
Tscan Stock prices reflect investors' perceptions of the future prospects and financial health of Tscan Therapeutics, and Tscan Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tscan Stock performance.
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (31.10) % | ||||
| Current Valuation | (45.15 M) | ||||
| Shares Outstanding | 52.23 M | ||||
| Price To Earning | 23.45 X | ||||
| Price To Book | 0.59 X | ||||
| Price To Sales | 14.49 X | ||||
| Revenue | 21.05 M | ||||
| Gross Profit | (91.04 M) | ||||
| EBITDA | (80.1 M) | ||||
| Net Income | (89.22 M) | ||||
| Cash And Equivalents | 125.6 M | ||||
| Cash Per Share | 5.22 X | ||||
| Total Debt | 92.43 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 4.29 X | ||||
| Cash Flow From Operations | (61.36 M) | ||||
| Earnings Per Share | (0.95) X | ||||
| Market Capitalization | 135.61 M | ||||
| Total Asset | 272.15 M | ||||
| Retained Earnings | (247.6 M) | ||||
| Working Capital | 164.42 M | ||||
About Tscan Therapeutics Performance
Evaluating Tscan Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Tscan Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Tscan Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.31) | |
| Return On Capital Employed | (0.35) | (0.36) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.68) | (0.65) |
Things to note about Tscan Therapeutics performance evaluation
Checking the ongoing alerts about Tscan Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tscan Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tscan Therapeutics generated a negative expected return over the last 90 days | |
| Tscan Therapeutics has high historical volatility and very poor performance | |
| Tscan Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 21.05 M. Net Loss for the year was (89.22 M) with loss before overhead, payroll, taxes, and interest of (91.04 M). | |
| Tscan Therapeutics currently holds about 125.6 M in cash with (61.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tscan Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: TScan Therapeutics, Inc.s recent 14 percent pullback adds to one-year year losses, institutional owners may take drastic measures |
- Analyzing Tscan Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tscan Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Tscan Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tscan Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tscan Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tscan Therapeutics' stock. These opinions can provide insight into Tscan Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.